You are here

  • Home
  • Archive
  • Volume 15, Issue 8
  • Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab

Article info

Article menu
Download PDFPDF
Case Reports: Rare disease
Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab

Authors

  1. Correspondence to Dr Will Thomas; w.thomas1{at}nhs.net
View Full Text

Citation

Jackson EM, Harper S, Webb GJ, et al
Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab
BMJ Case Reports CP 2022;15:e250774.

Publication history

  • Accepted August 17, 2022
  • First published August 31, 2022.
Online issue publication 
August 31, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.